PM · 8-K · 20260918PR062621

Products and Technology

Philip Morris International Inc. · 2026-09-18 · Importance 58 · Surprise 42 · In source text

Since 2008, PMI has invested more than $16 billion to develop, scientifically substantiate and commercialize smoke-free products. FDA marketing authorizations cover Swedish Match’s General snus, ZYN nicotine pouches and versions of PMI’s IQOS devices and consumables, representing first-ever authorizations in their respective categories. FDA also granted Modified Risk Tobacco Product authorizations to versions of IQOS devices and consumables, General snus and 20 ZYN nicotine pouch variants.

Key facts

• Since 2008, PMI has invested over $16 billion to develop, scientifically substantiate and commercialize innovative smoke-free products. source
• Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of versions of PMI’s IQOS devices and consumables. source
• Versions of IQOS devices and consumables obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA in their respective category. source
• Twenty ZYN nicotine pouch variants obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA in their respective category. source
• Philip Morris International stated a long-term ambition to expand into wellness areas. source
• PMI has built scientific assessment capabilities notably in pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. source
• PMI’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. source

Impact estimates